Loading...
•
Dec 31, 2024
•/
Haleon Q3 2024 Earnings Report
Haleon reported solid revenue growth and strong financial performance in Q4 2024.
Key Takeaways
Haleon achieved organic revenue growth of 6.8% in Q4 2024, driven by a combination of price and volume/mix improvements. The company's total revenue for the quarter reached £2.85 billion. Adjusted diluted EPS was 4.48p. The company saw continued strength in its Oral Health and Vitamins, Minerals, and Supplements (VMS) segments, while Pain Relief and Respiratory Health faced some headwinds.
Organic revenue growth in Q4 2024 was 6.8%, with price contributing 3.7% and volume/mix 3.1%.
Adjusted diluted EPS for Q4 2024 was 4.48p.
Strong revenue growth in Oral Health and VMS categories, with double-digit growth in Sensodyne and Centrum.
Respiratory Health faced a softer cold and flu season, impacting performance.
Haleon
Haleon
Haleon Revenue by Segment
Haleon Revenue by Geographic Location
Revenue by Segment
Oral Health Revenue
CapyFin.comVMS Revenue
CapyFin.comPain Relief Revenue
CapyFin.comRespiratory Health Revenue
CapyFin.comDigestive Health & Other Revenue
CapyFin.comRevenue by Geographic Location
North America Revenue
CapyFin.comEMEA & LatAm Revenue
CapyFin.comAPAC Revenue
CapyFin.com Forward Guidance
Haleon expects continued organic revenue growth in 2025, targeting 4-6% growth, with a focus on brand innovation and geographical expansion. However, foreign exchange and divestments may create headwinds.
Positive Outlook
- Expected organic revenue growth of 4-6% in 2025.
- Strong brand positioning in Oral Health and VMS categories.
- Continued investment in innovation and new product development.
- Further expansion into emerging markets, particularly India and China.
- £500m allocated to share buybacks in 2025.
Challenges Ahead
- Potential foreign exchange headwinds affecting revenue and profit growth.
- Impact of recent divestments expected to reduce revenue growth by approximately 2.0%.
- Regulatory changes in key markets may affect pricing and product availability.
- Increased competition in Pain Relief and Respiratory Health segments.
- Continued investments in A&P and R&D could pressure margins.
Revenue & Expenses
Visualization of income flow from segment revenue to net income